The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Nipun Merchant joins Sylvester Comprehensive Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NIPUN MERCHANT is joining the Sylvester Comprehensive Cancer Center as chief surgical officer and director of Surgical Oncology Research Programs.

Merchant will also take on the newly created position of vice chair of Surgical Oncologic Services and Academic Affairs within the Department of Surgery, and will be the chief of Surgical Oncology at University of Miami Hospital as well as chief surgical officer at UMHC/Sylvester. In addition, he will serve as chief of the Division of Surgical Oncology.

He comes to the University of Miami from Vanderbilt University Medical Center, where he has been the director of the Vanderbilt Pancreas Center, chief of GI Surgical Oncology and co-leader of the GI Oncology Program at Vanderbilt-Ingram Comprehensive Cancer Center.

As vice chair, he will lead the clinical and research enterprises of surgical oncology and oversee the educational and academic programs. Merchant’s clinical practice is in GI malignancies with a focus on hepatobiliary and pancreatic cancers.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo
ClinicalTrials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
By Enrique Velazquez-Villarreal
Sponsored

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
By Journal of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account